Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.
IPO Year: 2021
Exchange: NASDAQ
Website: orthoclinicaldiagnostics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/17/2022 | $21.00 | In-Line → Outperform | Evercore ISI Group |
| 12/27/2021 | $24.68 | Buy → Neutral | HC Wainwright & Co. |
| 12/27/2021 | $29.00 → $25.00 | Overweight → Equal-Weight | Barclays |
| 12/23/2021 | Outperform → In-Line | Evercore ISI Group | |
| 10/4/2021 | $27.00 | Buy | Citigroup |
| 8/5/2021 | $27.00 → $30.00 | Buy | HC Wainwright & Co. |
| 8/5/2021 | $23.00 | Outperform | Credit Suisse |
| 7/13/2021 | $24.00 → $27.00 | Overweight | Barclays |
SC 13G - Ortho Clinical Diagnostics Holdings plc (0001828443) (Subject)
SC 13G - Ortho Clinical Diagnostics Holdings plc (0001828443) (Subject)
RARITAN, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close on Wednesday, May 4, 2022. Ortho Clinical Diagnostics will hold a conference call the same day at 4:30 pm ET to discuss the results. Interested parties can access the call and accompanying presentation on the "Investors" portion of the Company's website at https://ir.orthoclinicaldiagnostics.com/. Presentation materials will also be posted to the "Investors" portion of the website at the time of the call. Thos
Highlights • Fourth quarter Core revenue grew 3.5% to $518.9 million, or 4.3% in constant currency and 8.0% excluding CoV-2 assay sales • Fiscal year Core revenue grew 16.1% to $2.01 billion, or 14.6% in constant currency and 15.7% excluding CoV-2 assay sales • Fourth quarter Operating income was $31.1 million, while Adjusted EBITDA was $127.9 million • Fiscal year Operating income was $173.9 million, while Adjusted EBITDA was $548.1 million, up 20.2% year-over-year RARITAN, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) (the "Company"), one of the world's largest pure-play in-vitro diagnostics (IVD) companies, today announced financial
Expects 4Q Reported and Constant Currency Core Revenue Growth of ~4%Fiscal Year Reported and Constant Currency Core Revenue Growth of ~16% and ~15%, respectively RARITAN, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) (the "Company"), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced preliminary unaudited revenue results for the fourth quarter and fiscal year ended January 2, 2022. The Company is providing these updates in advance of its presentation at the J.P. Morgan Healthcare Conference on January 11, 2022. Selected Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results (Unaudit
Strategic, transformational acquisition advances Quidel's global leadership in diagnostics Transaction Highlights Brings together highly complementary diagnostic portfolios with world-class technologies and platforms spanning high-throughput systems to near-patient and at-home testing. Provides Quidel's expansive point-of-care diagnostics portfolio with access to Ortho's broad global reach across 130-plus countries, accelerating growth for Quidel's existing product portfolio and providing exposure to new, emerging markets. Deepens innovation pipeline, diversifies product portfolio, and accelerates product growth, driving sustainable revenue in a combined total addressable market of $
Strong Revenue Growth Drives Financial Results Company Raises Fiscal 2021 Guidance Across all Key Metrics Highlights Third quarter revenue increased 15.8% to $522.5 million, or 14.3% in constant currency Core revenue grew 14.8% to $508.9 million for the quarter, or 13.2% in constant currency Strength across all major geographic regions, including double-digit growth in both developed and emerging markets Operating income increased 161.0% to $54.0 million from $20.7 million last year GAAP Net Income was $14.7 million, or $0.06 per diluted share, while Adjusted Net Income was $50.9 million, or $0.21 per diluted share in the third quarter of 2021 Third quarter Adjuste
RARITAN, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its third quarter 2021 ended October 3, 2021, after the market close on Wednesday, November 3, 2021. Ortho Clinical Diagnostics will hold a conference call the same day at 5:00 pm ET to discuss the results. Interested parties can access the call and accompanying presentation on the "Investors" portion of the Company's website at https://ir.orthoclinicaldiagnostics.com/. Presentation materials will also be posted to the "Investors" portion of the website at the time of the
Strong Revenue Growth Drives Financial Results Company Raises Fiscal 2021 Guidance Across all Key Metrics RARITAN, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX), one of the world's largest pure-play in-vitro diagnostics (IVD) companies, today announced financial results for the second quarter ended July 4, 2021. Highlights Second quarter revenue increased 26.1% to $492.5 million, or 22.4% in constant currencyCore revenue grew 26.2% to $487.5 million for the quarter, or 22.5% in constant currency Operating Income increased 104.7% to $31.3 million from $15.3 million last yearGAAP Net Loss was ($20.0) million, or ($0.09) per diluted share,
RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (NASDAQ:OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its second quarter 2021 ended July 4, 2021, after the market close on Wednesday, August 4, 2021. Ortho Clinical Diagnostics will hold a conference call the same day at 5:00 pm ET to discuss the results. Interested parties can access the call and accompanying presentation on the "Investors" portion of the Company's website at https://ir.orthoclinicaldiagnostics.com/. Presentation materials will also be posted to the "Investors" portion of the website at the time of the call. Those unable to
Evercore ISI Group upgraded Ortho Clinical Diagnostic from In-Line to Outperform and set a new price target of $21.00
HC Wainwright & Co. downgraded Ortho Clinical Diagnostic from Buy to Neutral and set a new price target of $24.68
Barclays downgraded Ortho Clinical Diagnostic from Overweight to Equal-Weight and set a new price target of $25.00 from $29.00 previously
Evercore ISI Group downgraded Ortho Clinical Diagnostic from Outperform to In-Line
Citigroup resumed coverage of Ortho Clinical Diagnostics with a rating of Buy and set a new price target of $27.00
HC Wainwright & Co. reiterated coverage of Ortho Clinical Diagnostic with a rating of Buy and set a new price target of $30.00 from $27.00 previously
Credit Suisse resumed coverage of Ortho Clinical Diagnostics with a rating of Outperform and set a new price target of $23.00
Barclays reiterated coverage of Ortho Clinical Diagnostic with a rating of Overweight and set a new price target of $27.00 from $24.00 previously
Credit Suisse reiterated coverage of Ortho Clinical Diagnostic with a rating of Outperform and set a new price target of $23.00 from $21.00 previously
Morgan Stanley reiterated coverage of Ortho Clinical Diagnostic with a rating of Overweight and set a new price target of $25.00 from $24.00 previously
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
15-12B - Ortho Clinical Diagnostics Holdings plc (0001828443) (Filer)
8-K - Ortho Clinical Diagnostics Holdings plc (0001828443) (Filer)
25-NSE - Ortho Clinical Diagnostics Holdings plc (0001828443) (Subject)
8-K - Ortho Clinical Diagnostics Holdings plc (0001828443) (Filer)
8-K - Ortho Clinical Diagnostics Holdings plc (0001828443) (Filer)
8-K/A - Ortho Clinical Diagnostics Holdings plc (0001828443) (Filer)
8-K/A - Ortho Clinical Diagnostics Holdings plc (0001828443) (Filer)
8-K - Ortho Clinical Diagnostics Holdings plc (0001828443) (Filer)
425 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Subject)
8-K - Ortho Clinical Diagnostics Holdings plc (0001828443) (Filer)
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Quidel Corporation (NASDAQ:QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc ("Ortho"), one of the world's larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022. On May 26, 2022, the High Court of Justice of England and Wales issued an order under Part 26 of the UK Companies Act sanctioning the scheme of arrangement to be undertaken by Ortho in connection with the business combinations (the "Ortho Scheme Order")
Quidel Corporation (NASDAQ:QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc ("Ortho"), one of the world's larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022. On May 26, 2022, the High Court of Justice of England and Wales issued an order under Part 26 of the UK Companies Act sanctioning the scheme of arrangement to be undertaken by Ortho in connection with the business combinations (the "Ortho Scheme Order"). The order will become effective once the Or
RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) ("Ortho" or the "Company"), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation (NASDAQ:QDEL) ("Quidel") pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto (the "BCA"). The closing of the transactions contemplated by the BCA is subject to sanction of the combination by the High Court of Justice of England and W
Highlights • Core revenue declined (0.9%) to $495.0 million, and grew 0.6% in constant currency and 4.2% excluding CoV-2 assay sales, which was a 4% headwind • Growth, excluding CoV-2 assay sales, was driven by Americas, EMEA, and ASPAC regions • Operating income was $47.1 million, while Adjusted EBITDA was $139.5 million • GAAP EPS was $0.06 while Adjusted Diluted EPS was $0.23, up $0.01 y/y after normalizing the share count for our February 2021 IPO RARITAN, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) (the "Company" or "Ortho Clinical Diagnostics"), one of the world's largest pure-play in-vitro diagnostics (IVD) companies, today announce
RARITAN, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (NASDAQ:OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious Gold 2022 Edison Award for its VITROS® Anti-SARS-CoV-2 IgG Quantitative Test COVID-19 testing solutions, helping labs meet demands of the pandemic with reliable mass-scale testing options. The Edison Awards is an annual competition honoring excellence in new products and service development, marketing, design, and innovation. The awards committee recognized Ortho's impact on the health care community and the only standardized test calibrated to the World Health Organization Standard. "
RARITAN, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close on Wednesday, May 4, 2022. Ortho Clinical Diagnostics will hold a conference call the same day at 4:30 pm ET to discuss the results. Interested parties can access the call and accompanying presentation on the "Investors" portion of the Company's website at https://ir.orthoclinicaldiagnostics.com/. Presentation materials will also be posted to the "Investors" portion of the website at the time of the call. Thos
RARITAN, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (NASDAQ:OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been awarded a Bronze 2022 Stevie® Award for Sales and Customer Service Department of the Year. The award further recognizes the company's commitment to excellence through Ortho Care® Service and Support, the company's global, award-winning service and support program. Ortho Care Service and Support is a holistic model that incorporates sophisticated technology and service offerings to help lab professionals maximize their experience and take full advantage of the advanced products Ortho provides. "The Stevie® Awards i
Highlights • Fourth quarter Core revenue grew 3.5% to $518.9 million, or 4.3% in constant currency and 8.0% excluding CoV-2 assay sales • Fiscal year Core revenue grew 16.1% to $2.01 billion, or 14.6% in constant currency and 15.7% excluding CoV-2 assay sales • Fourth quarter Operating income was $31.1 million, while Adjusted EBITDA was $127.9 million • Fiscal year Operating income was $173.9 million, while Adjusted EBITDA was $548.1 million, up 20.2% year-over-year RARITAN, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) (the "Company"), one of the world's largest pure-play in-vitro diagnostics (IVD) companies, today announced financial
RARITAN, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Further to the joint announcement by Ortho and Quidel Corporation ("Quidel") on December 23, 2021 of the signing of a definitive business combination agreement, Ortho announces that, as a preliminary procedural step in the process of implementing the combination, Ortho has scheduled a hearing of the High Court of Justice of England and Wales (the "UK Court") to seek the UK Court's consent and directions to convene a meeting of Ortho shareholders as part of the scheme of arrangement of Ortho proposed to be made pursuant to Part 26 of the Companies Act 2006 (the "UK Scheme") for the purpose of implementing the business combination (the "UK Sch
Expects 4Q Reported and Constant Currency Core Revenue Growth of ~4%Fiscal Year Reported and Constant Currency Core Revenue Growth of ~16% and ~15%, respectively RARITAN, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) (the "Company"), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced preliminary unaudited revenue results for the fourth quarter and fiscal year ended January 2, 2022. The Company is providing these updates in advance of its presentation at the J.P. Morgan Healthcare Conference on January 11, 2022. Selected Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results (Unaudit
Morgan Stanley maintains Ortho Clinical Diagnostic (NASDAQ:OCDX) with a Equal-Weight and raises the price target from $16.9 to $18.19.
Ortho Clinical Diagnostic (NASDAQ:OCDX) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.20 by 15 percent. This is a 11.54 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $495.00 million which missed the analyst consensus estimate of $508.21 million by 2.60 percent. This is a 2.33 percent decrease over sales of $506.80 million the same period last year.
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million. • Obsidian Energy (AMEX:OBE) is projected to report quarterly earnings at $0.41 per share on revenue of $156.00 million. • International Seaways (NYSE:INSW) is estimated to report quarterly loss at $0.31 per share on revenue of $96.75 million. • Bright Health Gr (NYSE:BHG) is projected to report quarterly loss at $0.24 per share on revenue of $1.75 billion. • OneSpaWorld Holdings (NASDAQ:OSW) is expected to report quarterly loss at $0.04 per share on revenue of $84.76 million. • Deciphera Pharmaceuticals (NASDAQ:DCPH) is likely
-Reuters
Upgrades HSBC upgraded the previous rating for Equinor ASA (NYSE:EQNR) from Hold to Buy. For the fourth quarter, Equinor had an EPS of $1.35, compared to year-ago quarter EPS of $0.17. The current stock performance of Equinor shows a 52-week-high of $32.16 and a 52-week-low of $17.78. Moreover, at the end of the last trading period, the closing price was at $29.45. Argus Research upgraded the previous rating for Canadian National Railway Co (NYSE:CNI) from Hold to Buy. For the fourth quarter, Canadian National Railway had an EPS of $1.36, compared to year-ago quarter EPS of $1.10. The current stock performance of Canadian National Railway shows a 52-week-high of $136.22 and a 52-week-low
Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) reported Q4 sales of $521 million, almost in line with the consensus of $521.17 million. The sales increased 0.8% on a reported basis, +1.6% on constant currency, and excluding CoV-2 assays, sales increased 5.0%. Core Revenue increased 3.5% to $518.9 million, up 4.3% on constant currency and +8% excluding CoV-2 assays. Gross profit margin improved 40 basis points to 50.5% from 50.1% last year. Related: Quidel To Buy Ortho Clinical Diagnostics For $24.68/Share: Highlights. The company reported an adjusted EPS of $0.18, down from $0.19 a year ago, beating the consensus of $0.15. The adjusted EBITDA declined 4.2% to $127.9 million.
Evercore ISI Group analyst Vijay Kumar upgrades Ortho Clinical Diagnostic (NASDAQ:OCDX) from In-Line to Outperform and announces $21 price target.
Ortho Clinical Diagnostic (NASDAQ:OCDX) reported its Q4 earnings results on Wednesday, February 16, 2022 at 04:30 PM. Here's what investors need to know about the announcement. Earnings Ortho Clinical Diagnostic beat estimated earnings by 20.0%, reporting an EPS of $0.18 versus an estimate of $0.15. Revenue was up $4.40 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.07, which was followed by a 4.84% increase in the share price the next day. Here's a look at Ortho Clinical Diagnostic's past performance: Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020 EPS Estimate 0.14 0.14 0.16 0.20
Ortho Clinical Diagnostic (NASDAQ:OCDX) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.15 by 20 percent. This is a 5.26 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $521.00 million which missed the analyst consensus estimate of $521.17 million by 0.03 percent. This is a 0.85 percent increase over sales of $516.60 million the same period last year.
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million. • Golden Ocean Group (NASDAQ:GOGL) is projected to report quarterly earnings at $8.24 per share on revenue of $2.72 billion. • Driven Brands Holdings (NASDAQ:DRVN) is likely to report quarterly earnings at $0.16 per share on revenue of $355.19 million. • Borr Drilling (NYSE:BORR) is estimated to report quarterly loss at $0.24 per share on revenue of $76.60 million. • SiteOne Landscape Supply (NYSE:SITE) is projected to report quarterly earnings at $0.27 per share on revenue of $745.48 million. • Urban Edge Props (NYSE:UE) is likely to rep